Search results for "228"

showing 10 items of 834 documents

Type B Aortic Dissection Diagnosed by Left-Sided Transthoracic Ultrasonography in a Woman With Preeclampsia

2017

Chest Painmedicine.medical_specialty030204 cardiovascular system & hematologyLeft sidedPreeclampsiaYoung Adult03 medical and health sciencesText mining0302 clinical medicinePre-Eclampsia030202 anesthesiologyPregnancymedicineHumansUltrasonographyAortic Aneurysm Thoracicbusiness.industryType B aortic dissectionGeneral Medicinemedicine.diseaseAbdominal PainSurgeryAortic DissectionTreatment OutcomeAnesthesiology and Pain Medicine030228 respiratory systemFemaleRadiologyUltrasonographybusiness030217 neurology & neurosurgeryAnesthesia & Analgesia
researchProduct

Triggers of Exacerbation in Chronic Urticaria and Recurrent Angioedema—Prevalence and Relevance

2021

Patients with urticaria and angioedema often have triggers that cause an outbreak or a swelling episode or worsen their chronic condition. Exploring these factors with each patient may result in better understanding and control of their disease. Patients should be advised to avoid known triggers, if feasible, or prepare to prevent or control an exacerbation with appropriate pretreatment if avoidance is not possible. In this review, we describe and discuss a variety of factors for which there is evidence that they cause or exacerbate chronic spontaneous urticaria and angioedema. These potentially exacerbating factors include drugs, food additives, and naturally occurring pseudoallergens, men…

Chronic conditionmedicine.medical_specialtyUrticariaExacerbationDiseaseImmunoglobulin EC1-inhibitor03 medical and health sciences0302 clinical medicineimmune system diseasesPrevalencemedicineHumansImmunology and AllergyChronic Urticaria030212 general & internal medicineAngioedemaskin and connective tissue diseasesIntensive care medicineChronic urticariabiologyAngioedemabusiness.industrymedicine.disease030228 respiratory systemChronic DiseaseHereditary angioedemabiology.proteinmedicine.symptombusinessThe Journal of Allergy and Clinical Immunology: In Practice
researchProduct

Effects of sleep apnea and kidney dysfunction on objective sleep quality in nondialyzed patients with chronic kidney disease: an ESADA study

2020

Study Objectives: Patients with chronic kidney disease (CKD) often report poor sleep quality, but they commonly exhibit OSA. The aim of this study was to evaluate the influence of OSA severity and of estimated glomerular filtration rate impairment on objective sleep quality in nondialyzed patients with CKD, defined as an estimated glomerular filtration rate <60 mL/min/1.73m2. Methods: Polysomnographic sleep characteristics were compared between patients with (n = 430) and without CKD (n = 6,639) in the European Sleep Apnea Database cohort. Comparisons were repeated in 375 patients with CKD and 375 control patients without CKD matched for sleep center, age, sex, and AHI, and in 310 matche…

Chronic kidney disease ; Estimated glomerular filtration rate ; Sleep apnea ; Sleep qualitysleep quality.Pulmonary and Respiratory Medicinemedicine.medical_specialtyRenal functionSettore MED/10 - Malattie Dell'Apparato RespiratorioKidneyurologic and male genital diseases03 medical and health sciencesSleep Apnea Syndromes0302 clinical medicinestomatognathic systemChronic kidney diseaseInternal medicineHumansMedicineEstimated glomerular filtration rateRenal Insufficiency ChronicSleep Apnea ObstructiveSleep qualitybusiness.industrySleep apneaKidney dysfunctionSleep apneaSleep qualitymedicine.diseaseScientific Investigationsfemale genital diseases and pregnancy complicationsnervous system diseasesrespiratory tract diseasesPoor sleep030228 respiratory systemNeurologyHuman medicineNeurology (clinical)Sleepbusiness030217 neurology & neurosurgeryKidney diseaseJournal of Clinical Sleep Medicine
researchProduct

Impact of temperature on obstructive sleep apnoea in three different climate zones of Europe: Data from the European Sleep Apnoea Database (ESADA)

2021

Recent studies indicate that ambient temperature may modulate obstructive sleep apnoea (OSA) severity. However, study results are contradictory warranting more investigation in this field. We analysed 19,293 patients of the European Sleep Apnoea Database (ESADA) cohort with restriction to the three predominant climate zones according to the Koppen-Geiger climate classification: Cfb (warm temperature, fully humid, warm summer), Csa (warm temperature, summer dry, hot summer), and Dfb (snow, fully humid, warm summer). Average outside temperature values were obtained and several hierarchical regression analyses were performed to investigate the impact of temperature on the apnea-hypopnea index …

Cognitive NeuroscienceSettore MED/10 - Malattie Dell'Apparato RespiratorioEnvironmentcomputer.software_genreBody Mass IndexCohort Studies03 medical and health sciencesBehavioral NeuroscienceSleep Apnea SyndromeSleep Apnea Syndromes0302 clinical medicineEnvironmental temperaturestomatognathic systemHumansMedicineOxygen saturation (medicine)Climate zonesSleep Apnea ObstructiveOxygen desaturationDatabasebusiness.industryTemperatureSleep Apnea Obstructive.General MedicineSleep in non-human animalsSleep-related breathing disordersnervous system diseasesrespiratory tract diseasesClinical neurologysleep&#8208030228 respiratory systemClimate zonerelated breathing disorderssleep-related breathing disorderHuman medicineCohort StudiebusinessBody mass indexcomputer030217 neurology & neurosurgeryHumanJournal of Sleep Research
researchProduct

Contingency plan for the intensive care services for the COVID-19 pandemic☆☆☆

2020

In January 2020, the Chinese authorities identified a new virus of the Coronaviridae family as the cause of several cases of pneumonia of unknown aetiology. The outbreak was initially confined to Wuhan City, but then spread outside Chinese borders. On 31 January 2020, the first case was declared in Spain. On 11 March 2020, The World Health Organization (WHO) declared the coronavirus outbreak a pandemic. On 16 March 2020, there were 139 countries affected. In this situation, the Scientific Societies SEMICYUC and SEEIUC, have decided to draw up this Contingency Plan to guide the response of the Intensive Care Services. The objectives of this plan are to estimate the magnitude of the problem a…

Contingency planPandemiaCoronavirus disease 2019 (COVID-19)Pandemicbusiness.industryUnknown aetiologySARS-CoV-2OutbreakCOVID-19030208 emergency & critical care medicinemedicine.diseaseWorld healthArticleCoronavirus03 medical and health sciences0302 clinical medicine030228 respiratory systemIntensive careMaterial resourcesPandemicmedicineMedical emergencybusinessMedicina Intensiva
researchProduct

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review

2020

Abstract Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety. Methods MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020. Results We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group,…

Coronavirus COVID-19 Pneumonia SARS-CoV-2 TocilizumabGCA Giant cell arteritispJIA Pediatric juvenile idiopathic arthritislaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawMedicine030212 general & internal medicineClinical efficacyCPAP Continuous positive airway pressureCOVID-19 Coronavirus disease 2019IDSA Infectious Diseases Society of AmericaRA Rheumatoid arthritisTocilizumabIMV Invasive mechanical ventilationsJIA Juvenile idiopathic arthritisAIFA Agenzia Italiana del FarmacoPulmonary and Respiratory Medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINEAntibodies Monoclonal HumanizedNIH U.S. National Institutes of HealthArticleWHO World Health OrganizationSIMIT Italian Society of Infectious and Tropical disease03 medical and health sciencesTocilizumabARDS Acute respiratory distress syndromeAnimalsHumansIn patientIntensive care medicineTocilizumab ; COVID-19 ; Pneumonia ; SARS-CoV-2 ; Coronaviruslcsh:RC705-779business.industryCRS CAR-T cell-induced cytokine release syndromeInterleukin-6SARS-CoV-2NIV Noninvasive mechanical ventilationTNF Tumor necrosis factorCOVID-19Pneumonialcsh:Diseases of the respiratory systemCOVID-19 Drug TreatmentClinical trialCoronavirus030228 respiratory systemchemistrybusinessICTRP International Clinical Trials Registry PlatformPulmonology
researchProduct

Contingency plan for the intensive care services for the COVID-19 pandemic

2020

Resumen En enero de 2020 China identifico un nuevo virus de la familia de los Coronaviridae como causante de varios casos de neumonia de origen desconocido. Inicialmente confinado a la ciudad de Wuhan, se extendio posteriormente fuera de las fronteras chinas. En Espana, el primer caso se declaro el 31 de enero de 2020. El 11 de marzo, la Organizacion Mundial de la Salud declaro el brote de coronavirus como pandemia. El 16 de marzo habia 139 paises afectados. Ante esta situacion, las Sociedades Cientificas SEMICYUC y SEEIUC han decidido la elaboracion de este plan de contingencia para dar respuesta a las necesidades que conllevara esta nueva enfermedad. Se pretende estimar la magnitud del pr…

Coronavirus03 medical and health sciences0302 clinical medicineCritical Care030228 respiratory systemCoronavirusesEpidemiology030208 emergency & critical care medicinePneumòniaPneumoniaCritical Care and Intensive Care MedicineCritical Care NursingEpidemiologia
researchProduct

Sepsis and Coronavirus Disease 2019: Common Features and Anti-Inflammatory Therapeutic Approaches

2020

Great efforts are being made worldwide to identify the specific clinical characteristics of infected critically ill patients that mediate the associated pathogenesis, including vascular dysfunction, thrombosis, dysregulated inflammation, and respiratory complications. Recently, coronavirus disease 2019 has been closely related to sepsis, which suggests that most deaths in ICUs in infected patients are produced by viral sepsis. Understanding the physiopathology of the disease that lead to sepsis after severe acute respiratory syndrome coronavirus 2 infection is a current clinical need to improve intensive care-applied therapies applied to critically ill patients. Although the whole represent…

Critical CareAnti-Inflammatory AgentsInflammationDiseaseCritical Care and Intensive Care MedicinesepsisSepsisPathogenesis03 medical and health sciences0302 clinical medicineImmune systemCoagulopathymedicineHumansanti-inflammatory therapyGlucocorticoidsRespiratory Distress SyndromeSARS-CoV-2business.industryCOVID-19Thrombosis030208 emergency & critical care medicineBlood Coagulation Disordersmedicine.diseaseThrombosisPathophysiologyViewpoints030228 respiratory systemcytokine stormImmunologyCytokinesmedicine.symptombusinesssevere acute respiratory syndrome coronavirus 2Critical Care Medicine
researchProduct

Respiratory support techniques to avoid desaturation in critically ill patients requiring endotracheal intubation: A systematic review and meta-analy…

2017

Abstract Purpose To evaluate which respiratory support method for critically ill patients undergoing endotracheal intubation (ETI) is associated with less desaturation. Methods We searched PubMed, Cochrane Library, Scopus and CINAHL databases. We included randomized (RCT) and non-randomized (non-RCT) studies investigating any method of respiratory support before/during ETI compared to a reference control. Results Apneic oxygenation (ApOx) was the most commonly investigated respiratory support technique for critically ill patients undergoing intubation (4 RCTs, 358 patients). Three of these studies investigated high-flow nasal cannula (HFNC) for ApOx while standard nasal cannula was used in …

Critical CareDatabases Factualmedicine.medical_treatmentAirway management; Apneic oxygenation; Endotracheal intubation; Noninvasive ventilation; Oxygen inhalation therapy; PreoxygenationCritical IllnessSettore MED/41 - AnestesiologiaEndotracheal intubationAirway managementCochrane LibraryCritical Care and Intensive Care Medicinemedicine.disease_causelaw.invention03 medical and health sciences0302 clinical medicineApneic oxygenationRandomized controlled triallawPreoxygenationmedicineIntubation IntratrachealIntubationCannulaHumansMED/41 - ANESTESIOLOGIAHypoxiabusiness.industryOxygen inhalation therapy030208 emergency & critical care medicineEndotracheal intubationRespiration ArtificialIntubation procedure030228 respiratory systemMeta-analysisAnesthesiaCritical IllneAirway managementbusinessRespiratory InsufficiencyNasal cannulaNoninvasive ventilationHuman
researchProduct

Can the response to Omalizumab be influenced by treatment duration? A real-life study

2017

Objective It is unknown whether Omalizumab effectiveness changes over the course of time. Our retrospective real-life study tried to analyze whether Omalizumab response may be influenced by treatment duration. Methods 340 severe asthmatics treated with Omalizumab for different periods of time were recruited. They were subdivided into 4 groups according to the Omalizumab treatment length: 60 months. Omalizumab treatment results (FEV1, exacerbations, ACT, SABA use, asthma control levels, medications used e and ICS doses) were compared. Results ACT, exacerbations, GINA control levels, ICS doses and SABA use were similar in all groups with different Omalizumab treatment durations. Using a linea…

CyclopropanesMaleSevere asthmaTime FactorsTreatment durationQuinolineEffectivenessOmalizumabOmalizumabAcetatesAdrenal Cortex Hormone0302 clinical medicineAdrenal Cortex HormonesRetrospective StudieForced Expiratory VolumeMedicinePharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineLead (electronics)Adrenergic beta-AgonistConfoundingEffectiveneReal-lifeResponseAdrenergic beta-AgonistsMiddle AgedTreatment OutcomeEffectiveness; Omalizumab; Real-life; Response; Severe asthma; Treatment duration; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)QuinolinesLinear ModelFemaleHumanmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyTime FactorSulfidesSettore MED/10 - Malattie Dell'Apparato RespiratorioTreatment duration03 medical and health sciencesInternal medicineHumansAnti-Asthmatic AgentMontelukastRetrospective StudiesAsthmaAcetatebusiness.industryBiochemistry (medical)Retrospective cohort studymedicine.diseaseAsthmaDiscontinuationSurgery030228 respiratory systemLinear ModelsbusinessPulmonary Pharmacology & Therapeutics
researchProduct